AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,967,954 | -11.9% | 326,312 | -9.0% | 0.00% | 0.0% |
| Q2 2023 | $4,504,669 | +39.4% | 358,652 | +23.1% | 0.00% | +33.3% |
| Q1 2023 | $3,231,781 | -4.0% | 291,414 | +5.7% | 0.00% | -25.0% |
| Q4 2022 | $3,366,932 | +19.8% | 275,752 | +2.5% | 0.00% | +33.3% |
| Q3 2022 | $2,810,000 | +2.4% | 269,146 | +5.4% | 0.00% | 0.0% |
| Q2 2022 | $2,743,000 | +7.7% | 255,378 | -5.1% | 0.00% | +50.0% |
| Q1 2022 | $2,548,000 | -6.2% | 269,163 | +14.4% | 0.00% | +100.0% |
| Q4 2021 | $2,716,000 | +15.9% | 235,203 | -4.1% | 0.00% | 0.0% |
| Q3 2021 | $2,343,000 | -9.0% | 245,316 | -8.1% | 0.00% | 0.0% |
| Q2 2021 | $2,575,000 | -1.7% | 267,074 | +0.8% | 0.00% | 0.0% |
| Q1 2021 | $2,619,000 | -73.6% | 265,060 | -38.4% | 0.00% | -80.0% |
| Q4 2020 | $9,936,000 | +107.3% | 430,286 | +26.7% | 0.01% | +66.7% |
| Q3 2020 | $4,794,000 | -31.8% | 339,529 | -27.2% | 0.00% | -40.0% |
| Q2 2020 | $7,032,000 | +156.8% | 466,323 | +57.4% | 0.01% | +150.0% |
| Q1 2020 | $2,738,000 | -16.6% | 296,284 | -12.1% | 0.00% | 0.0% |
| Q4 2019 | $3,282,000 | +101.2% | 336,988 | +65.7% | 0.00% | +100.0% |
| Q3 2019 | $1,631,000 | -33.4% | 203,429 | +3.6% | 0.00% | -50.0% |
| Q2 2019 | $2,449,000 | +8.6% | 196,295 | +18.3% | 0.00% | 0.0% |
| Q1 2019 | $2,255,000 | +19.8% | 165,861 | -15.5% | 0.00% | 0.0% |
| Q4 2018 | $1,882,000 | -28.6% | 196,359 | -9.9% | 0.00% | 0.0% |
| Q3 2018 | $2,636,000 | -68.5% | 218,006 | -59.3% | 0.00% | -75.0% |
| Q2 2018 | $8,359,000 | -72.1% | 535,221 | -73.2% | 0.01% | -71.4% |
| Q1 2018 | $30,007,000 | -26.6% | 1,995,169 | -29.7% | 0.03% | -24.3% |
| Q4 2017 | $40,855,000 | +43.4% | 2,839,041 | +50.3% | 0.04% | +37.0% |
| Q3 2017 | $28,482,000 | +1732.8% | 1,888,742 | +1123.0% | 0.03% | +1250.0% |
| Q2 2017 | $1,554,000 | -25.8% | 154,435 | -47.4% | 0.00% | 0.0% |
| Q1 2017 | $2,095,000 | +128.2% | 293,835 | +58.9% | 0.00% | +100.0% |
| Q4 2016 | $918,000 | -15.1% | 184,929 | +26.7% | 0.00% | 0.0% |
| Q3 2016 | $1,081,000 | +5.4% | 145,963 | -22.3% | 0.00% | 0.0% |
| Q2 2016 | $1,026,000 | -22.8% | 187,811 | +19.4% | 0.00% | -50.0% |
| Q1 2016 | $1,329,000 | +19.2% | 157,270 | +36.7% | 0.00% | +100.0% |
| Q4 2015 | $1,115,000 | +25.0% | 115,016 | +80.3% | 0.00% | 0.0% |
| Q3 2015 | $892,000 | -70.9% | 63,778 | -70.6% | 0.00% | -66.7% |
| Q2 2015 | $3,067,000 | +6.1% | 216,756 | -18.4% | 0.00% | 0.0% |
| Q1 2015 | $2,891,000 | +98.3% | 265,718 | +51.7% | 0.00% | +200.0% |
| Q4 2014 | $1,458,000 | +153.1% | 175,106 | +81.0% | 0.00% | – |
| Q3 2014 | $576,000 | +329.9% | 96,752 | +141.4% | 0.00% | – |
| Q2 2014 | $134,000 | -18.8% | 40,085 | -49.6% | 0.00% | – |
| Q1 2014 | $165,000 | -9.8% | 79,592 | +2.7% | 0.00% | – |
| Q4 2013 | $183,000 | +35.6% | 77,524 | +33.1% | 0.00% | – |
| Q3 2013 | $135,000 | -46.9% | 58,260 | -46.6% | 0.00% | – |
| Q2 2013 | $254,000 | -50.6% | 109,141 | -32.6% | 0.00% | -100.0% |
| Q1 2013 | $514,000 | – | 162,009 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |